Brentuximab vedotin

(Adcetris®)

Brentuximab vedotin

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 50 mg)
Drug ClassCD30-directed anitbody-drug conjugates
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine in adult patients.
  • For the treatment of classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as postautologous hematopoietic stem cell transplantation (auto-HSCT) consolidation in adult patients.
  • For the treatment of classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates in adult patients.
  • For the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone in adult patients.
  • For the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen in adult patients.
  • For the treatment of primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy in adult patients.

Product Monograph / Prescribing Information

Document TitleYearSource
Adcetris (brentuximab vedotin) Prescribing Information. 2023Seagen Inc., Bothell, WA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Assessment report: Adcetris.2023EMA
Assessment report: Adcetris.2023EMA
Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.2023European Journal of Clinical Pharmacology
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma.2023Expert Review of Hematology
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis.2022NICE
Efficacy of brentuximab vedotin and nivolumab in refractory or relapsed hodgkin lymphoma: a systematic review.2022Cureus
Assessment report: Adcetris.2021EMA
Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.2021Leukemia & Lymphoma
Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.2021European Review for Medical and Pharmacological Sciences
Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology Group.2021Journal of Pediatric Oncology Nursing
Clinical review report: brentuximab vedotin (Adcetris) for hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine.2020CADTH
Final clinical guidance report: brentuximab vedotin (Adcetris) for peripheral t-cell lymphoma.2020CADTH
Final clinical guidance report: brentuximab vedotin (Adcetris) for primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.2020CADTH
Risk of adverse events in lymphoma patients treated with brentuximab vedotin: a systematic review and meta-analysis.2020Expert Opinion on Drug Safety
Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.2020British Journal of Haematology
A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma.2020Leukemia & Lymphoma
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.2020Expert Review of Hematology
The clinical and humanistic burden of cutaneous T-cell lymphomas and response to conventional and novel therapies: results of a systematic review.2020Expert Review of Hematology
Clinical review report: brentuximab (Adcetris) for Hodgkin lymphoma resubmission.2019CADTH
Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs).2019Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
Clinical review report: brentuximab (Adcetris) for Hodgkin lymphoma (post-ASCT) resubmission.2018CADTH

Clinical Practice Guidelines